Tiziana Life Sciences Ltd (NASDAQ:TLSA) Short Interest Update

Tiziana Life Sciences Ltd (NASDAQ:TLSA) was the target of a significant drop in short interest during the month of November. As of November 30th, there was short interest totalling 208,100 shares, a drop of 24.3% from the November 15th total of 274,900 shares. Based on an average trading volume of 261,300 shares, the days-to-cover ratio is presently 0.8 days. Approximately 0.3% of the shares of the stock are sold short.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Tiziana Life Sciences stock. Zhang Financial LLC increased its stake in shares of Tiziana Life Sciences Ltd (NASDAQ:TLSA) by 24.2% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 69,387 shares of the company’s stock after purchasing an additional 13,500 shares during the quarter. Zhang Financial LLC owned approximately 0.07% of Tiziana Life Sciences worth $67,000 at the end of the most recent reporting period.

Tiziana Life Sciences Stock Performance

Shares of TLSA remained flat at $0.94 during midday trading on Friday. The stock had a trading volume of 67,138 shares, compared to its average volume of 263,146. Tiziana Life Sciences has a one year low of $0.41 and a one year high of $1.74. The company’s 50 day moving average price is $0.95 and its two-hundred day moving average price is $0.97.

Tiziana Life Sciences Company Profile

Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases.